Publications by authors named "Fernando G Ang"
Article Synopsis
- The study aimed to determine if the duration of type 2 diabetes affects how canagliflozin influences cardiovascular and kidney outcomes.
- An analysis was conducted on two major trials involving over 14,500 participants to assess the impact of canagliflozin on various outcomes related to heart and kidney health, particularly focusing on changes in albumin levels over different durations of diabetes.
- Results indicated that canagliflozin consistently benefits cardiovascular and kidney health regardless of how long a person has had type 2 diabetes, suggesting that early treatment is advantageous.
Background: This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).
Methods And Results: This was a pooled participant-level analysis of the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program and CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. The CANVAS Program included participants with type 2 diabetes at elevated cardiovascular risk, whereas the CREDENCE trial included participants with type 2 diabetes and albuminuric chronic kidney disease.
Aim: In the CANVAS Program and CREDENCE trials, the sodium glucose co-transporter 2 inhibitor canagliflozin reduced the risk of cardiovascular and kidney events in patients with type 2 diabetes. The current study analysed a pooled population to ascertain the kidney protection provided by canagliflozin across the full spectrum of kidney parameters.
Methods: This post-hoc pooled analysis of the CANVAS Program (N = 10 142) and CREDENCE trial (N = 4401), assessed the risk of the primary kidney composite (doubling of serum creatinine, end-stage kidney disease, renal death), in all patients and subgroups defined by baseline estimated glomerular filtration rate (<30, 30 to <45, 45 to <60 and ≥60 ml/min/1.